Autophagic pathways as new targets for cancer drug development

Bo Liu, Yan Cheng, Qian Liu, Jin Ku Bao, Jin Ming Yang

Research output: Contribution to journalReview article

84 Citations (Scopus)

Abstract

Autophagy is an evolutionarily conserved lysosomal self-digestion process involved in degradation of long-lived proteins and damaged organelles. In recent years, increasing evidence indicates that autophagy is associated with a number of pathological processes, including cancer. In this review, we focus on the recent studies of the evolutionarily conserved autophagy-related genes (ATGs) that are implicated in autophagosome formation and the pathways involved. We discuss several key autophagic mediators (eg, Beclin-1, UVRAG, Bcl-2, Class III and I PI3K, mTOR, and p53) that play pivotal roles in autophagic signaling networks in cancer. We discuss the Janus roles of autophagy in cancer and highlighted their relationship to tumor suppression and tumor progression. We also present some examples of targeting ATGs and several protein kinases as anticancer strategy, and discuss some autophagy-modulating agents as antitumor agents. A better understanding of the relationship between autophagy and cancer would ultimately allow us to harness autophagic pathways as new targets for drug discovery in cancer therapeutics.

Original languageEnglish (US)
Pages (from-to)1154-1164
Number of pages11
JournalActa Pharmacologica Sinica
Volume31
Issue number9
DOIs
StatePublished - Sep 1 2010

Fingerprint

Autophagy
Pharmaceutical Preparations
Neoplasms
Pathologic Processes
Drug Discovery
Phosphatidylinositol 3-Kinases
Organelles
Antineoplastic Agents
Protein Kinases
Digestion
Proteins
Genes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Liu, B., Cheng, Y., Liu, Q., Bao, J. K., & Yang, J. M. (2010). Autophagic pathways as new targets for cancer drug development. Acta Pharmacologica Sinica, 31(9), 1154-1164. https://doi.org/10.1038/aps.2010.118
Liu, Bo ; Cheng, Yan ; Liu, Qian ; Bao, Jin Ku ; Yang, Jin Ming. / Autophagic pathways as new targets for cancer drug development. In: Acta Pharmacologica Sinica. 2010 ; Vol. 31, No. 9. pp. 1154-1164.
@article{a99c47de3c144a09a5a34c5beeb2ffce,
title = "Autophagic pathways as new targets for cancer drug development",
abstract = "Autophagy is an evolutionarily conserved lysosomal self-digestion process involved in degradation of long-lived proteins and damaged organelles. In recent years, increasing evidence indicates that autophagy is associated with a number of pathological processes, including cancer. In this review, we focus on the recent studies of the evolutionarily conserved autophagy-related genes (ATGs) that are implicated in autophagosome formation and the pathways involved. We discuss several key autophagic mediators (eg, Beclin-1, UVRAG, Bcl-2, Class III and I PI3K, mTOR, and p53) that play pivotal roles in autophagic signaling networks in cancer. We discuss the Janus roles of autophagy in cancer and highlighted their relationship to tumor suppression and tumor progression. We also present some examples of targeting ATGs and several protein kinases as anticancer strategy, and discuss some autophagy-modulating agents as antitumor agents. A better understanding of the relationship between autophagy and cancer would ultimately allow us to harness autophagic pathways as new targets for drug discovery in cancer therapeutics.",
author = "Bo Liu and Yan Cheng and Qian Liu and Bao, {Jin Ku} and Yang, {Jin Ming}",
year = "2010",
month = "9",
day = "1",
doi = "10.1038/aps.2010.118",
language = "English (US)",
volume = "31",
pages = "1154--1164",
journal = "Acta Pharmacologica Sinica",
issn = "1671-4083",
publisher = "Nature Publishing Group",
number = "9",

}

Liu, B, Cheng, Y, Liu, Q, Bao, JK & Yang, JM 2010, 'Autophagic pathways as new targets for cancer drug development', Acta Pharmacologica Sinica, vol. 31, no. 9, pp. 1154-1164. https://doi.org/10.1038/aps.2010.118

Autophagic pathways as new targets for cancer drug development. / Liu, Bo; Cheng, Yan; Liu, Qian; Bao, Jin Ku; Yang, Jin Ming.

In: Acta Pharmacologica Sinica, Vol. 31, No. 9, 01.09.2010, p. 1154-1164.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Autophagic pathways as new targets for cancer drug development

AU - Liu, Bo

AU - Cheng, Yan

AU - Liu, Qian

AU - Bao, Jin Ku

AU - Yang, Jin Ming

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Autophagy is an evolutionarily conserved lysosomal self-digestion process involved in degradation of long-lived proteins and damaged organelles. In recent years, increasing evidence indicates that autophagy is associated with a number of pathological processes, including cancer. In this review, we focus on the recent studies of the evolutionarily conserved autophagy-related genes (ATGs) that are implicated in autophagosome formation and the pathways involved. We discuss several key autophagic mediators (eg, Beclin-1, UVRAG, Bcl-2, Class III and I PI3K, mTOR, and p53) that play pivotal roles in autophagic signaling networks in cancer. We discuss the Janus roles of autophagy in cancer and highlighted their relationship to tumor suppression and tumor progression. We also present some examples of targeting ATGs and several protein kinases as anticancer strategy, and discuss some autophagy-modulating agents as antitumor agents. A better understanding of the relationship between autophagy and cancer would ultimately allow us to harness autophagic pathways as new targets for drug discovery in cancer therapeutics.

AB - Autophagy is an evolutionarily conserved lysosomal self-digestion process involved in degradation of long-lived proteins and damaged organelles. In recent years, increasing evidence indicates that autophagy is associated with a number of pathological processes, including cancer. In this review, we focus on the recent studies of the evolutionarily conserved autophagy-related genes (ATGs) that are implicated in autophagosome formation and the pathways involved. We discuss several key autophagic mediators (eg, Beclin-1, UVRAG, Bcl-2, Class III and I PI3K, mTOR, and p53) that play pivotal roles in autophagic signaling networks in cancer. We discuss the Janus roles of autophagy in cancer and highlighted their relationship to tumor suppression and tumor progression. We also present some examples of targeting ATGs and several protein kinases as anticancer strategy, and discuss some autophagy-modulating agents as antitumor agents. A better understanding of the relationship between autophagy and cancer would ultimately allow us to harness autophagic pathways as new targets for drug discovery in cancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=77956363593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956363593&partnerID=8YFLogxK

U2 - 10.1038/aps.2010.118

DO - 10.1038/aps.2010.118

M3 - Review article

C2 - 20694022

AN - SCOPUS:77956363593

VL - 31

SP - 1154

EP - 1164

JO - Acta Pharmacologica Sinica

JF - Acta Pharmacologica Sinica

SN - 1671-4083

IS - 9

ER -